Nimesulide Efficacy

The efficacy of nimesulide (100mg twice daily) was compared with that of naproxen (500mg twice daily) in 53 adult patients with nonbacterial acute inflammation of the ear, nose or throat in a double-blind phase III clinical investigation. Both drugs were administered orally after meals for a mean duration of 8.7 days.

In this setting, nimesulide was associated with relief of pain and inflammatory signs (exudation and swelling). Indeed, treatment with nimesulide led to clinical improvement superior to that obtained with naproxen in terms of both rapidity of action and improvement of the symptoms at the end of therapy. Nimesulide therapy was also very well tolerated and no patient reported an adverse event. In contrast, 2 naproxen-treated patients reported episodic gastralgia of moderate intensity.

Nimesulide's therapeutic value in effectively and rapidly controlling inflammation and pain is supported by significant clinical evidence.

Clinical studies have been carried out in a wide variety of acute inflammatory and painful conditions with the aim of evaluating the analgesic activity of nimesulide in comparison to placebo and to some of the most common NSAIDs.

In these studies, the efficacy of nimesulide was consistently superior to placebo and at least comparable, or in some cases superior, to that observed for the reference drugs, with a particularly fast onset of the analgesic action.

Nimesulide posses analgesic properties with multifactorial mode of action for the treatment of musculoskeletal system, dysmenorrhoea, and acute pain.
The abilities of NSAID’s drug nimesulide to inhibit COX-2 preferentially and to exert other novel anti-inflammatory actions are consistent with good efficacy and safety with highly effective in reducing pain, inflammation and also helps in better penetration of the antibiotics.

It also undergoes extensive biotransformation. The recent study on the basis of analgesic activity of Nimesulide has proved that it has a quicker onset which shows relief from pain relief and inflammation within 15 minutes from drug intake.

Nimesulide is recommended for the shortest duration necessary to control symptoms in patients with acute pain or primary dysmenorrhoea.